Warning Letter to Nature’s Benefit

February 12, 2008

Department of Health and Human Services' logo Department of Health and Human Services

Public Health Service
Food and Drug Administration
Center for Food Safety and Applied Nutrition


Office of Nutritional Products, Labeling and Dietary Supplements
Division of Dietary Supplement Programs
College Park, MD 20740

October 4, 2006

Stephen Holt, MD
Nature’s Benefit
61 Stevens Ave
Little Falls, NJ 07424

Ref. No. CL-06-HFS-810-244

Dear Dr Holt:

This is to advise you that the Food and Drug Administration (FDA) has reviewed your website at the Internet address www.naturesbenefit.com and has determined that the products “Hoodia Supreme Plus™,” “Syndrome X Nutrition Factors™,” “Green Tea Max™,” and “Holt’s Diabetic Fish Oil™” are promoted for conditions that cause the products to be drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 USC 321(g)(1)]. The therapeutic claims on your website establish that the products are drugs because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The marketing of these products with these claims violates the Act.

Examples of some of the claims observed on your website include:

[on your website page for your product Hoodia Supreme Plus™]
“This revolutionary product addresses metabolic problems of obesity, found in the metabolic syndrome X.”
[on your website page for your product Syndrome X Nutrition Factors™]
“Syndrome X is the variable combination of obesity, insulin resistance, high blood cholesterol and hypertension. These factors cause early coronary artery (heart) disease. Americas #1 Killer Is Cardiovascular Disease! Syndrome X is a horrifying epidemic affecting about 70 million Americans. People with Syndrome X may ask these questions, without recognizing their problem: …

  • Why do I have high blood pressure or cholesterol?”
[on your website page for your product Green Tea Max™]
“[P]opulation studies indicate that green tea consumption in eastern Asia has been responsible for … anti-cancer effects ….”
[on your website page for your product Holt’s Diabetic Fish Oil™]
“It is the omega 3 fatty acids found in high quality pure fish oils that is health-giving for the person with diabetes. … Holt’s Diabetic Fish Oil™ is a new generation of essential omega 3 fatty acids …. “The value of omega 3 fatty acids in the promotion of health and well being in the individual with diabetes mellitus has been grossly underestimated in modern medicine. Scientific literature shows that fish oil in certain concentrations may have benefits in … stroke prevention, … and anti-inflammatory actions. … Many governments have permitted health claims to be made about the value of omega 3 fatty acids which have special purpose in the maintenance of health in the individual with diabetes mellitus, pre-diabetes and the metabolic Syndrome X.”

Furthermore, your products are not generally recognized as safe and effective for the above referenced conditions and therefore, the products are also “new drugs” under section 201(p) of the Act [21 USC 321(p)]. New drugs may not be legally marketed in the US without prior approval from FDA as described in section 505(a) of the Act [21 USC 355(a)]. FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective.

FDA is aware that Internet distributors may not know that the products they offer are regulated as drugs or that these drugs are not in compliance with the law. Many of these products may be legally marketed as dietary supplements if claims about diagnosis, cure, mitigation, treatment, or prevention are removed from the promotional materials and the products otherwise comply with all applicable provisions of the Act and FDA regulations.

Under the Act, as amended by the Dietary Supplement Health and Education Act, dietary supplements may be legally marketed with truthful and non-misleading claims to affect the structure or function of the body (structure/function claims), if certain requirements are met. However, claims that dietary supplements are intended to prevent, diagnose, mitigate, treat, or cure disease (disease claims), excepting health claims authorized for use by FDA, cause the products to be drugs. The intended use of a product may be established through product labels and labeling, catalogs, brochures, audio and videotapes, Internet sites, or other circumstances surrounding the distribution of the product. FDA has published a final rule intended to clarify the distinction between structure/function claims and disease claims. This document is available on the Internet at vm.cfsan.fda.gov/~lrd/fr000106.html (codified at 21 CFR 101.93(g)).

In addition, only products that are intended for ingestion may be lawfully marketed as dietary supplements. Topical products and products intended to enter the body directly through the skin or mucosal tissues, such as transdermal or sublingual products, are not dietary supplements. For these products, both disease and structure/function claims may cause them to be new drugs.

Certain over-the-counter drugs are not new drugs and may be legally marketed without prior approval from FDA. Additional information is available in Title 21 of the Code of Federal Regulations (21 CFR) Parts 310 and 330-358, which contain FDA’s regulations on over-the-counter drugs.

This letter is not intended to be an all-inclusive review of your website and products your firm markets. It is your responsibility to ensure that all products marketed by your firm comply with the Act and its implementing regulations.

If you need additional information or have questions concerning any products distributed through your website, please contact FDA. You may respond in writing to Linda J. Webb, Compliance Officer, Food and Drug Administration, Division of Dietary Supplement Programs, 5100 Paint Branch Pkwy, College Park, MD 20740-3835. If you have any questions concerning this letter, please contact Ms Webb at 301-436-2375.

Sincerely yours,
Vasilios H. Frankos, PhD
Acting Division Director

This page was posted on February 12, 2008.